BG34-200 Immunotherapy of Advanced Melanoma
by
,
Veronique Roche
1,2,†,
Victor Sandoval
1,2,3,†,
Zachary Senders
1,2,3,
Joshua Lyons
1,2,3,
Claire Wolford
1,2 and
Mei Zhang
1,2,3,* 1
Department of Biomedical Engineering, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106, USA
2
Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA
3
University Hospitals Cleveland Medical Center, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44016, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2022, 14(23), 5911; https://doi.org/10.3390/cancers14235911
Submission received: 21 October 2022
/
Revised: 18 November 2022
/
Accepted: 26 November 2022
/
Published: 30 November 2022
(This article belongs to the Collection Emerging Therapeutics in Advanced Melanoma)
Simple Summary
Immunotherapy using immune checkpoint inhibitors is now the first line standard of care for advanced melanoma but >50% of patients still do not benefit. Using a recently developed plant-derived glucan molecule called BG34-200, we found that targeting elements of the myeloid components are useful in creating systemic antitumor immune responses in advanced melanoma. Scientific findings from this study suggest that BG34-200-based combination therapy can be developed to benefit patients with advanced melanoma who do not respond to current standard of care therapies with and without immunotherapy.
Abstract
High levels of myeloid-derived cells are characteristic of the tumor microenvironment (TME) of advanced melanoma. These cells interact with tumor cells to suppress the development of antitumor immune responses, regulate tumor metastasis, and drive cancer’s resistance to virtually all types of therapy. Therefore, methods to disrupt tumor-associated myeloid cell function are actively being sought to find a cure. Our team has recently developed a plant-derived carbohydrate molecule, BG34-200, that modulates tumor-associated myeloid cells by targeting the cell surface receptor CD11b. In this study, we found that BG34-200 IV administration could significantly inhibit tumor growth and improve survival in B16F10 mice with advanced melanoma. Our data supported a model that the entry of BG34-200 into circulating melanoma tumor-associated inflammatory monocytes (TAIMs) could trigger a sequential immune activation: the BG34-200+ TAIM subsets migrated to tumor and differentiated into monocyte-derived dendritic cells (mo-DCs); then, the BG34-200+ mo-DCs migrated to tumor draining lymph nodes, where they triggered the generation of tumor-antigen-specific T cells. Based upon these results, we combined BG34-200 treatment with adoptive transfer of TdLN-derived T cells to treat advanced melanoma, which significantly improved animal survival and helped tumor-free survivors be resistant to a second tumor-cell challenge. The scientific findings from this study will allow us to develop new technology and apply BG34-200-based immunotherapy to patients with advanced melanoma who have not responded to current standard of care therapies with and without immunotherapy.
